ストックスクリーナーアプリを入手
16.82
0.24%
-0.04
アフターアワーズ：
16.83
0.010
+0.06%
前日終値:
$16.86
開ける：
$16.99
24時間の取引高:
945.50K
Relative Volume:
1.16
時価総額：
$683.15M
収益：
-
当期純損益:
$-168.05M
株価収益率:
-3.2788
EPS:
-5.13
ネットキャッシュフロー:
$-146.15M
1週間 パフォーマンス:
-2.77%
1か月 パフォーマンス:
+10.73%
6か月 パフォーマンス:
+18.95%
1年 パフォーマンス:
-68.93%
1日の値動き範囲:
$16.78
$18.42
1週間の範囲:
$16.31
$18.42
52週間の値動き範囲:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
名前
Keros Therapeutics Inc
セクター
電話
617-314-6297
住所
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
16.82 | 513.66M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-01-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-12-16 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-16 | 繰り返されました | Oppenheimer | Outperform |
| 2024-12-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-12 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-12-12 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-12-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 開始されました | Jefferies | Buy |
| 2024-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-09-23 | 開始されました | Guggenheim | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-02-21 | 開始されました | William Blair | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-07-31 | 開始されました | Wedbush | Outperform |
| 2023-07-26 | 開始されました | BofA Securities | Buy |
| 2023-02-14 | 開始されました | Cowen | Outperform |
| 2022-10-18 | 開始されました | Truist | Buy |
| 2022-07-26 | 開始されました | BTIG Research | Buy |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-04 | 開始されました | Jefferies | Buy |
| 2020-05-04 | 開始されました | Piper Sandler | Overweight |
| 2020-05-04 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Keros Therapeutics Inc (KROS) 最新ニュース
Keros Therapeutics announces final results of tender offer - MarketScreener
Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - MarketScreener
Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
How to manage a losing position in Keros Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
How to recover losses in Keros Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Is Keros Therapeutics Inc. stock attractive for income investors2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Will Keros Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Summary & Daily Chart Pattern Signals - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Will Keros Therapeutics Inc. price bounce be sustainable2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Evaluating Keros Therapeutics Inc. with trendline analysisEntry Point & Short-Term Trading Opportunity Alerts - newser.com
Can volume confirm reversal in Keros Therapeutics Inc.July 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Will Keros Therapeutics Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat
Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq
Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating - MarketScreener
Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat
Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation - Nasdaq
KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig - GuruFocus
Keros Therapeutics Drives Nasdaq Composite Momentum In Medicine - Kalkine Media
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - sharewise.com
How interest rate cuts could boost Keros Therapeutics Inc. stockDay Trade & AI Enhanced Execution Alerts - newser.com
KROS vs. ARGX: Which Stock Is the Better Value Option? - sharewise.com
Why Keros Therapeutics Inc. stock remains undervaluedJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
What is HC Wainwright's Estimate for KROS FY2025 Earnings? - MarketBeat
FY2025 EPS Estimate for Keros Therapeutics Lifted by Analyst - MarketBeat
FY2025 EPS Forecast for Keros Therapeutics Raised by Analyst - MarketBeat
Will Keros Therapeutics Inc. stock deliver consistent dividendsWeekly Profit Recap & Verified Technical Trade Signals - newser.com
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - news.stocktradersdaily.com
Keros Therapeutics Inc (KROS) 財務データ
収益
当期純利益
現金流量
EPS
0.67%
0.43%
大文字化:
|
ボリューム (24 時間):